Story thread · 2 reports / 2 sources

Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide

financialpost.com · 14dShare

TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related study documents for the Company’s ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”). Arch recently announced […]

First report: Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide — thestar.com, 14d